SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602369772> ?p ?o ?g. }

Showing items 1 to 100 of 100 with 100 items per page.

W2602369772 endingPage "11508" @default.
W2602369772 startingPage "11508" @default.
W2602369772 abstract "11508 Background: ETV1 and KIT are lineage-specific master transcriptional and signaling survival factors in GIST. In preclinical models, dual lineage targeting of ETV1 by MEK inhibition with BINI and KIT by imatinib are synergistic in suppressing GIST tumorigenesis and progression. This single-arm phase II study is designed to test the efficacy of the BINI+imatinib as a first-line treatment in patients (pts) with advanced GIST. Methods: Adult pts with untreated advanced GIST received imatinib (400mg daily) plus BINI (30mg twice daily), 28-day cycles. The primary endpoint (EP) was RECIST1.1 objective response rate (ORR) (complete response [CR]+partial response [PR]). The study was designed to detect a 20% improvement in the ORR of imatinib alone (unacceptable rate of 45%; acceptable rate of 65%). A sample size of 44 patients was required, using an exact binomial test, one-sided type I error of 0.08 and type II error of 0.1. Confirmed PR in > 24 pts would be considered positive. Secondary EPs included RR by Choi and EORTC criteria, resectability conversion rate (RCR), progression free survival (PFS), overall survival (OS) and long-term AEs. Correlatives included characterization of tumor genomics by MSK-IMPACT, cfDNA by MSK-ACCESS, ETV1 protein levels and transcriptomes and signaling inhibition. Results: At data cutoff of Jan 31, 2020, 38/39 pts with advanced GIST of all genotypes, including 3 KIT/PDGFRA-wild type GIST pts, were evaluable for primary EP. Median age 60 (range 29-78), 29% female. 26/38 pts with confirmed PR; Best ORR was 68.4% (two-sided 95% CI, 51-83%; one-sided 90% CI, 57-100%). 8/9 pts became resectable after treatment; RCR was 88.9% (95% CI, 52-100%). 13 pts remain on trial (2-159 weeks [wks]). 9 pts discontinued trial due to disease progression (11-159 wks); one pt progressed within 3 months, indicating primary resistance. Grade 3/4 toxicity included CPK elevation (asymptomatic, 61%), neutrophil decrease (11%), maculopapular rash (8%), anemia (8%). No unexpected toxicities observed. Correlation of outcome with MSK-IMPACT, MSK-Access and paired tumor biopsies will be presented. Conclusions: This study met its primary endpoint. BINI plus imatinib is highly effective in treatment-naive advanced GIST, with expected and manageable long-term treatment-associated toxicities. The combination strategy warrants further evaluation in direct comparison with imatinib in the frontline treatment of GIST. Clinical trial information: NCT01991379 ." @default.
W2602369772 created "2017-04-07" @default.
W2602369772 creator A5003762281 @default.
W2602369772 creator A5006374965 @default.
W2602369772 creator A5012215691 @default.
W2602369772 creator A5024743507 @default.
W2602369772 creator A5025014871 @default.
W2602369772 creator A5026770999 @default.
W2602369772 creator A5027745721 @default.
W2602369772 creator A5029520673 @default.
W2602369772 creator A5031037291 @default.
W2602369772 creator A5034595315 @default.
W2602369772 creator A5043833554 @default.
W2602369772 creator A5047174533 @default.
W2602369772 creator A5050033613 @default.
W2602369772 creator A5064214267 @default.
W2602369772 creator A5064406305 @default.
W2602369772 creator A5067158281 @default.
W2602369772 creator A5072876748 @default.
W2602369772 creator A5078755190 @default.
W2602369772 creator A5086786876 @default.
W2602369772 creator A5089731384 @default.
W2602369772 date "2020-05-20" @default.
W2602369772 modified "2023-09-27" @default.
W2602369772 title "A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST)." @default.
W2602369772 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.11508" @default.
W2602369772 hasPublicationYear "2020" @default.
W2602369772 type Work @default.
W2602369772 sameAs 2602369772 @default.
W2602369772 citedByCount "9" @default.
W2602369772 countsByYear W26023697722016 @default.
W2602369772 countsByYear W26023697722021 @default.
W2602369772 countsByYear W26023697722022 @default.
W2602369772 countsByYear W26023697722023 @default.
W2602369772 crossrefType "journal-article" @default.
W2602369772 hasAuthorship W2602369772A5003762281 @default.
W2602369772 hasAuthorship W2602369772A5006374965 @default.
W2602369772 hasAuthorship W2602369772A5012215691 @default.
W2602369772 hasAuthorship W2602369772A5024743507 @default.
W2602369772 hasAuthorship W2602369772A5025014871 @default.
W2602369772 hasAuthorship W2602369772A5026770999 @default.
W2602369772 hasAuthorship W2602369772A5027745721 @default.
W2602369772 hasAuthorship W2602369772A5029520673 @default.
W2602369772 hasAuthorship W2602369772A5031037291 @default.
W2602369772 hasAuthorship W2602369772A5034595315 @default.
W2602369772 hasAuthorship W2602369772A5043833554 @default.
W2602369772 hasAuthorship W2602369772A5047174533 @default.
W2602369772 hasAuthorship W2602369772A5050033613 @default.
W2602369772 hasAuthorship W2602369772A5064214267 @default.
W2602369772 hasAuthorship W2602369772A5064406305 @default.
W2602369772 hasAuthorship W2602369772A5067158281 @default.
W2602369772 hasAuthorship W2602369772A5072876748 @default.
W2602369772 hasAuthorship W2602369772A5078755190 @default.
W2602369772 hasAuthorship W2602369772A5086786876 @default.
W2602369772 hasAuthorship W2602369772A5089731384 @default.
W2602369772 hasConcept C126322002 @default.
W2602369772 hasConcept C143998085 @default.
W2602369772 hasConcept C16930146 @default.
W2602369772 hasConcept C203092338 @default.
W2602369772 hasConcept C2775922572 @default.
W2602369772 hasConcept C2777007597 @default.
W2602369772 hasConcept C2777583451 @default.
W2602369772 hasConcept C2778729363 @default.
W2602369772 hasConcept C37307934 @default.
W2602369772 hasConcept C535046627 @default.
W2602369772 hasConcept C71924100 @default.
W2602369772 hasConcept C90924648 @default.
W2602369772 hasConceptScore W2602369772C126322002 @default.
W2602369772 hasConceptScore W2602369772C143998085 @default.
W2602369772 hasConceptScore W2602369772C16930146 @default.
W2602369772 hasConceptScore W2602369772C203092338 @default.
W2602369772 hasConceptScore W2602369772C2775922572 @default.
W2602369772 hasConceptScore W2602369772C2777007597 @default.
W2602369772 hasConceptScore W2602369772C2777583451 @default.
W2602369772 hasConceptScore W2602369772C2778729363 @default.
W2602369772 hasConceptScore W2602369772C37307934 @default.
W2602369772 hasConceptScore W2602369772C535046627 @default.
W2602369772 hasConceptScore W2602369772C71924100 @default.
W2602369772 hasConceptScore W2602369772C90924648 @default.
W2602369772 hasIssue "15_suppl" @default.
W2602369772 hasLocation W26023697721 @default.
W2602369772 hasOpenAccess W2602369772 @default.
W2602369772 hasPrimaryLocation W26023697721 @default.
W2602369772 hasRelatedWork W1964805506 @default.
W2602369772 hasRelatedWork W1980642264 @default.
W2602369772 hasRelatedWork W2003962636 @default.
W2602369772 hasRelatedWork W2004598454 @default.
W2602369772 hasRelatedWork W2067256453 @default.
W2602369772 hasRelatedWork W2128064909 @default.
W2602369772 hasRelatedWork W2412807435 @default.
W2602369772 hasRelatedWork W2809726097 @default.
W2602369772 hasRelatedWork W3044902401 @default.
W2602369772 hasRelatedWork W3157027491 @default.
W2602369772 hasVolume "38" @default.
W2602369772 isParatext "false" @default.
W2602369772 isRetracted "false" @default.
W2602369772 magId "2602369772" @default.
W2602369772 workType "article" @default.